BAJAJ BROKING

Notification
No new Notification messages
Suraksha Diagnostic IPO is Open!
Apply for the Suraksha Diagnostic IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Q2 FY'24-25 Results of Top Companies
Reliance, TCS, HDFC Bank & more: Explore key financial highlights from India's top quarterly results.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
NSE BSE
aurobindo pharma ltd stock

AUROBINDO PHARMA LTD Share Price

1264.3 9.55 (0.76%)
Dec 03 2024 03:30 PM Pharmaceuticals NSE: AUROPHARMA

AUROBINDO PHARMA LTD Share Price Update

As of the latest trading session, AUROBINDO PHARMA LTD share price is currently at 1264.3, which is up by 9.55 from its previous closing. Today, the stock has fluctuated between 1242.00 and 1276.50. Over the past year, AUROBINDO PHARMA LTD has achieved a return of 20.34 %. In the last month alone, the return has been -10.83 %. Read More...

AUROBINDO PHARMA LTD Performance

Day Range

Low1242.00 High1276.50
1264.30

52 Week Range

Low 958.50 High 1592.00
1264.30

AUROBINDO PHARMA LTD Share Price

275

524804

AUROPHARMA

img img img img
No Data Available

Open Price

1265.00

Prev. Close

1254.75

Volume (Shares)

2128922.00

Total traded value

26915.96

Upper Circuit

1380.20

Lower Circuit

1129.30

Note: The current prices & values are delayed, Login to your account for live updates.

AUROBINDO PHARMA LTD Fundamentals


(Standalone)

Market Cap (Cr) 74080.23
PE Ratio (TTM) 35.86
Book Value / Share 335.47
Beta 0.57
ROE 10.35%
EPS (TTM) 35.31
Dividend Yield 0.36%
Net Profit Qtr (Cr) 537.53

AUROBINDO PHARMA LTD Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars SEP 2024 (Values in Cr)
Revenue 2757.88
Operating Expense 2223.50
Net Profit 537.53
Net Profit Margin (%) 19.49
Earnings Per Share (EPS) 9.21
EBITDA 843.54
Effective Tax Rate (%) 25.72
Particulars JUN 2024 (Values in Cr)
Revenue 2425.22
Operating Expense 2079.17
Net Profit 329.04
Net Profit Margin (%) 13.56
Earnings Per Share (EPS) 5.62
EBITDA 564.25
Effective Tax Rate (%) 26.26
Particulars MAR 2024 (Values in Cr)
Revenue 2866.40
Operating Expense 2237.12
Net Profit 578.67
Net Profit Margin (%) 20.18
Earnings Per Share (EPS) 9.88
EBITDA 897.76
Effective Tax Rate (%) 25.80
Particulars DEC 2023 (Values in Cr)
Revenue 2663.87
Operating Expense 2335.94
Net Profit 623.78
Net Profit Margin (%) 23.41
Earnings Per Share (EPS) 10.65
EBITDA 812.82
Effective Tax Rate (%) 9.23
Particulars SEP 2023 (Values in Cr)
Revenue 2648.41
Operating Expense 2226.06
Net Profit 415.74
Net Profit Margin (%) 15.69
Earnings Per Share (EPS) 7.10
EBITDA 612.26
Effective Tax Rate (%) 25.52
Particulars MAR 2024 (Values in Cr)
Revenue 10542.21
Operating Expense 8858.78
Net Profit 1954.14
Net Profit Margin (%) 18.53
Earnings Per Share (EPS) 33.35
EBITDA 2840.10
Effective Tax Rate (%) 20.92
Particulars MAR 2023 (Values in Cr)
Revenue 8371.54
Operating Expense 7269.93
Net Profit 1227.11
Net Profit Margin (%) 14.65
Earnings Per Share (EPS) 21.00
EBITDA 1948.83
Effective Tax Rate (%) 23.83
Particulars MAR 2022 (Values in Cr)
Revenue 11250.07
Operating Expense 10245.94
Net Profit 1454.71
Net Profit Margin (%) 12.93
Earnings Per Share (EPS) 24.83
EBITDA 2069.68
Effective Tax Rate (%) 11.16
Particulars MAR 2021 (Values in Cr)
Revenue 15622.18
Operating Expense 12220.53
Net Profit 3112.91
Net Profit Margin (%) 19.92
Earnings Per Share (EPS) 53.13
EBITDA 4709.69
Effective Tax Rate (%) 25.75
Particulars MAR 2020 (Values in Cr)
Revenue 13038.82
Operating Expense 11244.15
Net Profit 1876.88
Net Profit Margin (%) 14.39
Earnings Per Share (EPS) 32.03
EBITDA 2941.29
Effective Tax Rate (%) 20.80
Particulars MAR 2024 (Values in Cr)
Book Value / Share 509.35
ROE % 11.18
ROCE % 13.51
Total Debt to Total Equity 0.21
EBITDA Margin 21.35
Particulars MAR 2023 (Values in Cr)
Book Value / Share 458.10
ROE % 7.50
ROCE % 9.18
Total Debt to Total Equity 0.16
EBITDA Margin 16.08
Particulars MAR 2022 (Values in Cr)
Book Value / Share 419.46
ROE % 11.38
ROCE % 12.41
Total Debt to Total Equity 0.18
EBITDA Margin 19.39
Particulars MAR 2021 (Values in Cr)
Book Value / Share 374.29
ROE % 17.59
ROCE % 18.29
Total Debt to Total Equity 0.29
EBITDA Margin 22.84
Particulars MAR 2020 (Values in Cr)
Book Value / Share 287.16
ROE % 18.52
ROCE % 18.51
Total Debt to Total Equity 0.42
EBITDA Margin 21.71
Particulars MAR 2024 (Values in Cr)
Book Value / Share 336.62
ROE % 10.35
ROCE % 11.74
Total Debt to Total Equity 0.19
EBITDA Margin 27.19
Particulars MAR 2023 (Values in Cr)
Book Value / Share 307.80
ROE % 6.98
ROCE % 8.18
Total Debt to Total Equity 0.17
EBITDA Margin 22.87
Particulars MAR 2022 (Values in Cr)
Book Value / Share 292.15
ROE % 8.81
ROCE % 8.49
Total Debt to Total Equity 0.18
EBITDA Margin 18.34
Particulars MAR 2021 (Values in Cr)
Book Value / Share 271.80
ROE % 21.49
ROCE % 22.94
Total Debt to Total Equity 0.27
EBITDA Margin 29.76
Particulars MAR 2020 (Values in Cr)
Book Value / Share 222.78
ROE % 15.38
ROCE % 15.97
Total Debt to Total Equity 0.34
EBITDA Margin 23.09
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 6278.30
Total Assets 45071.51
Total Liabilities 45071.51
Total Equity 29850.80
Share Outstanding 585938609
Price to Book Ratio 3.24
Return on Assets (%) 7.03
Return on Capital (%) 8.77
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 6084.20
Total Assets 39889.99
Total Liabilities 39889.99
Total Equity 26851.85
Share Outstanding 585938609
Price to Book Ratio 1.68
Return on Assets (%) 4.83
Return on Capital (%) 6.08
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 4190.01
Total Assets 33921.72
Total Liabilities 33921.72
Total Equity 24574.05
Share Outstanding 585938609
Price to Book Ratio 2.29
Return on Assets (%) 7.80
Return on Capital (%) 9.83
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 5474.28
Total Assets 33853.99
Total Liabilities 33853.99
Total Equity 21928.99
Share Outstanding 585915609
Price to Book Ratio 3.24
Return on Assets (%) 15.75
Return on Capital (%) 19.83
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 2842.15
Total Assets 28927.74
Total Liabilities 28927.74
Total Equity 16824.81
Share Outstanding 585915609
Price to Book Ratio 1.85
Return on Assets (%) 9.83
Return on Capital (%) 12.79
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 94.34
Total Assets 25153.98
Total Liabilities 25153.98
Total Equity 19722.82
Share Outstanding 585938609
Price to Book Ratio 3.24
Return on Assets (%) 7.76
Return on Capital (%) 8.67
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 373.41
Total Assets 25058.81
Total Liabilities 25058.81
Total Equity 18034.03
Share Outstanding 585938609
Price to Book Ratio 1.68
Return on Assets (%) 4.89
Return on Capital (%) 5.53
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 50.78
Total Assets 21600.95
Total Liabilities 21600.95
Total Equity 17117.34
Share Outstanding 585938609
Price to Book Ratio 2.29
Return on Assets (%) 6.73
Return on Capital (%) 7.68
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 386.18
Total Assets 23188.99
Total Liabilities 23188.99
Total Equity 15924.61
Share Outstanding 585915609
Price to Book Ratio 3.24
Return on Assets (%) 13.42
Return on Capital (%) 15.66
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 86.16
Total Assets 19563.61
Total Liabilities 19563.61
Total Equity 13052.50
Share Outstanding 585915609
Price to Book Ratio 1.85
Return on Assets (%) 9.59
Return on Capital (%) 11.18
Particulars MAR 2024 (Values in Cr)
Net Income 4379.99
Cash from Operations 4201.16
Cash from Investing -4255.95
Cash from Financing 800.42
Net change in Cash -1021.01
Free Cash Flow 6981.49
Particulars MAR 2023 (Values in Cr)
Net Income 2612.50
Cash from Operations 3103.99
Cash from Investing -3977.75
Cash from Financing 1814.41
Net change in Cash 223.41
Free Cash Flow 5507.79
Particulars MAR 2022 (Values in Cr)
Net Income 3372.74
Cash from Operations 6274.67
Cash from Investing -3211.56
Cash from Financing -2969.27
Net change in Cash -1164.35
Free Cash Flow 8327.58
Particulars MAR 2021 (Values in Cr)
Net Income 7343.59
Cash from Operations 4614.30
Cash from Investing 598.69
Cash from Financing -1364.94
Net change in Cash 2562.80
Free Cash Flow 6052.24
Particulars MAR 2020 (Values in Cr)
Net Income 3743.04
Cash from Operations 5142.12
Cash from Investing -1567.64
Cash from Financing -1947.18
Net change in Cash 866.46
Free Cash Flow 6524.87
Particulars MAR 2024 (Values in Cr)
Net Income 2475.41
Cash from Operations 2316.98
Cash from Investing -159.96
Cash from Financing -1837.03
Net change in Cash -282.19
Free Cash Flow 2734.57
Particulars MAR 2023 (Values in Cr)
Net Income 1611.23
Cash from Operations 2116.80
Cash from Investing -3457.62
Cash from Financing 1719.48
Net change in Cash 78.03
Free Cash Flow 2470.55
Particulars MAR 2022 (Values in Cr)
Net Income 1637.48
Cash from Operations 4418.78
Cash from Investing -1613.51
Cash from Financing -2447.54
Net change in Cash -334.34
Free Cash Flow 5032.84
Particulars MAR 2021 (Values in Cr)
Net Income 4193.01
Cash from Operations 3621.38
Cash from Investing -2648.73
Cash from Financing -28.06
Net change in Cash 317.74
Free Cash Flow 4018.11
Particulars MAR 2020 (Values in Cr)
Net Income 2370.05
Cash from Operations 2580.07
Cash from Investing -951.68
Cash from Financing -1254.65
Net change in Cash -4.95
Free Cash Flow 3261.69
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 58.72 33.75 3.20 449.99 37.54 / 77.70
BLISS GVS PHARMA LTD 168.10 21.04 1.75 1770.13 92.25 / 172.40
CIPLA LTD 1508.10 26.38 4.29 121796.04 1192.85 / 1702.00
FERMENTA BIOTECH LIMITED 363.75 126.30 3.68 1070.55 145.00 / 399.60
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 58.72 51.06 9.98 449.99 37.54 / 77.70
AMRUTAJAN HEALTH LTD 740.85 45.06 7.19 2141.84 556.05 / 861.40
ASTRAZENECA PHARMA IND LT 6712.65 130.37 24.70 16781.63 4050.15 / 8139.85
BLISS GVS PHARMA LTD 168.10 21.89 1.72 1770.13 92.25 / 172.40

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 1247.40
  • 26 Days 1299.80
  • 10 Days 1242.90
  • 50 Days 1368.00
  • 12 Days 1245.20
  • 100 Days 1387.30
  • 20 Days 1278.80
  • 200 Days 1055.30
1257.58
PIVOT
First Resistance 1274.17
Second Resistance 1285.73
Third Resistance 1302.32
First Support 1246.02
Second Support 1229.43
Third Support 1217.87
RSI 35.95
MACD -54.63
Commodity Channel Index (CCI) -38.30
ADX 78.44
Williams % R -73.02

Over 1 Month

down

-10.83

Over 3 Months

down

-19.25

Over 6 Months

down

2.22

Over 1 Year

down

20.34

Over 3 Years

down

23.04

Over 5 Years

down

22.75

AUROBINDO PHARMA LTD Future

Future: Price

26 Dec
1270.00
30 Jan
1278.75
27 Feb
1265.75
25 May
0 100 200 300 400 500 600

Discount/Premium

26 Dec
5.70
30 Jan
14.45
27 Feb
1.45
25 May
0 1 2 3 4 5 6 7

Active Calls

1300.0
5448
1260.0
2803
1280.0
2503
25 May
0 500 1000 1500 2000 2500 3000

Active Puts

1240.0
1548
1200.0
1458
1260.0
1356
25 Jul
0 500 1000 1500 2000 2500

AUROBINDO PHARMA LTD Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Others
-13.92
Promoter Holdings
51.81
FII
16.59
DII
25.12
Promoter Shares(Pledge Percentage)
20.39
Name Category Shares Shares%
Rpr Sons Advisors Private Limited, Mrs.p.suneela Rani (jointly Holding) Shareholding of Promoter and Promoter Group 1.94561357E8 33.5
Hdfc Large And Mid Cap Fund Public Shareholding 2.5646956E7 4.42
K Nityananda Reddy Shareholding of Promoter and Promoter Group 2.5359572E7 4.37
Quant Mutual Fund - Quant Business Cycle Fund Public Shareholding 2.0923424E7 3.6
Kirthi Reddy Kambam Shareholding of Promoter and Promoter Group 2.0062852E7 3.45
Icici Prudential Manufacturing Fund Public Shareholding 1.843242E7 3.17
Venkata Ramprasad Reddy Penaka Shareholding of Promoter and Promoter Group 1.7833646E7 3.07
Axis Clinicals Limited, Trident Chemphar Limited, Rpr Sons Advisors Pvt.ltd. (jointly Holding) Shareholding of Promoter and Promoter Group 1.6572131E7 2.85
M Sivakumaran Shareholding of Promoter and Promoter Group 1.4357432E7 2.47
Mirae Asset Nifty Midcap 150 Etf Public Shareholding 1.3565618E7 2.34
Life Insurance Corporation Of India Public Shareholding 1.2072348E7 2.08
Nps Trust- A/c Icici Prudential Pension Fund Schem Public Shareholding 9108069.0 1.57
K Spoorthi Shareholding of Promoter and Promoter Group 6939173.0 1.19
K Rajeswari Shareholding of Promoter and Promoter Group 1808631.0 0.31
M Sumanth Kumar Reddy Shareholding of Promoter and Promoter Group 1585214.0 0.27
Trident Chemphar Limited Shareholding of Promoter and Promoter Group 782241.0 0.13
Axis Clinicals Limited Shareholding of Promoter and Promoter Group 651920.0 0.11
Prasada Reddy Kambham Shareholding of Promoter and Promoter Group 298373.0 0.05
Suneela Rani Penaka Shareholding of Promoter and Promoter Group 128799.0 0.02
Penaka Neha Reddy Shareholding of Promoter and Promoter Group 0.0 0.0
K Suryaprakash Reddy Shareholding of Promoter and Promoter Group 7380.0 0.0

AUROBINDO PHARMA LTD

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
2024-02-20 1.5 Interim 2 2024-02-20 Equity shares 2023-11-20 3.0 Interim 1 2023-11-20 Equity shares 2023-02-17 3.0 Interim 1 2023-02-17 Equity shares 2022-06-06 4.5 Interim 4 2022-06-07 Equity shares 2022-02-18 1.5 Interim 3 2022-02-21 Equity shares 2021-11-17 1.5 Interim 2 2021-11-18 Equity shares 2021-08-27 1.5 Interim 2021-08-30 Equity shares 2021-02-22 1.5 Interim 3 2021-02-23 Equity shares 2020-11-23 1.25 Interim 2 2020-11-24 Equity shares 2020-08-21 1.25 Interim 2020-08-25 Equity shares 2020-02-17 1.75 Interim 2 2020-02-18 Equity shares 2019-11-21 1.25 Interim 2019-11-23 Equity shares 2019-02-15 1.25 Interim 2 2019-02-19 Equity shares 2018-11-20 1.25 Interim 2 2018-11-22 Equity shares 2018-02-20 1.0 Interim 2 2018-02-21 Equity shares 2017-11-21 1.5 Interim 2017-11-22 Equity shares 2017-06-08 1.25 Interim 2 2017-06-09 Equity shares 2016-11-24 1.25 Interim 2016-11-25 Equity shares 2016-06-09 0.7 Interim 4 2016-06-10 Equity shares 2016-02-18 0.7 Interim 3 2016-02-22 Equity shares 2015-11-19 0.6 Interim 2 2015-11-20 Equity shares 2015-08-21 0.5 Interim 2015-08-25 Equity shares 2015-06-08 1.0 Interim 3 2015-06-09 Equity shares 2015-02-16 2.0 Interim 2 2015-02-18 Equity shares 2014-08-13 1.5 Interim 2014-08-19 Equity shares 2014-06-11 1.75 Interim 2 2014-06-12 Equity shares 2013-11-19 1.25 Interim 2013-11-20 Equity shares 2013-07-30 0.5 Final 2013-08-01 Equity shares 2013-02-18 1.0 Interim 2013-02-20 Equity shares 2012-07-30 1.0 Final 2012-08-01 Equity shares 2011-07-20 1.0 Final 2011-07-22 Equity shares 2010-11-11 5.0 Interim 2010-11-12 Equity shares 2010-09-13 2.0 Final 2010-09-15 Equity shares 2010-02-05 3.0 Interim 2010-02-08 Equity shares 2009-12-16 1.5 Final 2009-12-18 Equity shares 2009-02-05 3.0 Interim 2009-02-06 Equity shares 2008-08-11 3.25 Final 2008-08-13 Equity shares 2007-09-14 2.5 Final 2007-09-18 Equity shares 2005-09-20 0.0 Final 2005-09-22 Equity shares
Ex-Date Ex-Bonus Ratio
2015-07-21 2015-07-20 1:1 2000-04-01 2000-03-15 1:1 2000-04-01 2000-03-06 1:1 1998-11-19 1998-10-26 1:1
Ex-Date Old FV NEW FV Record Date
2011-02-10 5.0 1.0 2011-02-11 2003-10-23 10.0 5.0 2003-10-31

Aurobindo Pharma Share Result Highlights

Aurobindo Pharma reported Q2 revenue of ₹7,796 crore for this financial year, reflecting a YoY growth of 7.99%. Operating profit reached ₹1,566 crore with an OPM of 20%. Profit after tax stood at ₹817 crore, a YoY growth of 9%, despite a sequential dip from Q1 of this year. Over the last decade, compounded sales growth was 14%, and profit growth was 11%. Return on equity, over the same period was 16%.

Aurobindo Pharma Share Annual Reports

For FY24, Aurobindo Pharma achieved a 16.68% sales growth, reaching ₹29,002 crore compared to ₹24,859 crore in FY23. Net profit stood at ₹3,169 crore, highlighting moderate recovery despite lower profitability over recent years. EPS for the year was ₹54.15. The company’s 10-year compounded profit growth averaged 11%, but three-year growth remained stagnant at -1%. Return on equity, though stable, declined to 12% last year, reflecting the challenges in maintaining margins in a competitive sector. Aurobindo Pharma’s share price saw an increase of 19% in the last 1-year period.

Aurobindo Pharma Share Dividend

Aurobindo Pharma’s dividend payout declined to 8% in FY24, down from 23% in FY23, indicating a shift in financial priorities. The dividend yield for the year stood at a modest 0.37%. While the company’s long-term growth in sales and profits is robust, recent profit stagnation (-1% compounded growth over three years) and declining returns on equity have impacted dividend trends.

About AUROBINDO PHARMA LTD

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by AUROBINDO PHARMA LTD

Learn More About Stocks

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Additional FAQs

1. Who is the CEO of Aurobindo Pharma Ltd?

Mr. K. Nithyananda Reddy is the Vice Chairman and Managing Director of Aurobindo Pharma Ltd. He oversees the company’s operations and global pharmaceutical initiatives.

 

2. When was Aurobindo Pharma Ltd established?

Aurobindo Pharma Ltd was established in 1986 and has grown into a prominent pharmaceutical company with a significant presence in both domestic and international markets.

 

3. What factors influence the Aurobindo Pharma Share Price?

Aurobindo Pharma’s share price is influenced by factors such as regulatory approvals, the launch of new pharmaceutical products, revenue growth, and global market conditions for generics and APIs.

 

4. Is Aurobindo Pharma Ltd debt free?

No, Aurobindo Pharma Ltd is not debt free, as it utilises borrowings to support its manufacturing, research, and global expansion efforts.

 

5. What is the CAGR of Aurobindo Pharma Share?

The CAGR of Aurobindo Pharma’s share is 8% over 10 years, 22% over 5 years, and 22% over 3 years.

 

6. How has the Aurobindo Pharma Share Price performed over the past year?

Over the past year, Aurobindo Pharma’s share price has increased by 19%, reflecting improved business performance and market sentiment toward its pharmaceutical offerings.

 

Frequently Asked Questions

What is the Share Price of Aurobindo Pharma Ltd?

Answer Field

The share price of Aurobindo Pharma Ltd for NSE is ₹ 1264.3 and for BSE is ₹ 1266.25.

What is the Market Cap of Aurobindo Pharma Ltd?

Answer Field

The market cap of Aurobindo Pharma Ltd for NSE is ₹ 7,40,80.23 Cr. and for BSE is ₹ 7,41,94.48 Cr. as of now.

What is the 52 Week High and Low of Aurobindo Pharma Ltd?

Answer Field

The 52 Week High and Low of Aurobindo Pharma Ltd for NSE is ₹ 1592.00 and ₹ 958.50 and for BSE is ₹ 1592.55 and ₹ 959.05.

How to Buy Aurobindo Pharma Ltd share?

Answer Field

You can trade in Aurobindo Pharma Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Aurobindo Pharma Ltd?

Answer Field

The 1 year returns on the stock has been 20.34%.

What is the Current Share Price of Aurobindo Pharma Ltd?

Answer Field

Aurobindo Pharma Ltd share price is for NSE ₹ 1264.3 & for BSE ₹ 1266.25 as on Dec 03 2024 03:30 PM.

What is the Market Cap of Aurobindo Pharma Ltd Share?

Answer Field

The market cap of Aurobindo Pharma Ltd for NSE ₹ 7,40,80.23 & for BSE ₹ 7,41,94.48 as on Dec 03 2024 03:30 PM.

What is the P/E Ratio of Aurobindo Pharma Ltd Share?

Answer Field

As on Dec 03 2024 03:30 PM the price-to-earnings (PE) ratio for Aurobindo Pharma Ltd share is 35.86.

What is the PB ratio of Aurobindo Pharma Ltd Share?

Answer Field

As on Dec 03 2024 03:30 PM, the price-to-book (PB) ratio for Aurobindo Pharma Ltd share is 335.47.

How to Buy Aurobindo Pharma Ltd Share?

Answer Field

You can trade in Aurobindo Pharma Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Aurobindo Pharma Ltd Share on Bajaj Broking App?

Answer Field

To buy Aurobindo Pharma Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Aurobindo Pharma Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs + Users

icon-with-text

4.8+ App Rating

icon-with-text

4 Languages

icon-with-text

₹5000+ Cr MTF Book

icon-with-text
loader